

- secretagogues and with insulin. *Diabetes Care* 30:389–394, 2007
5. The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med* 358:2545–2559, 2008
 6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, for the VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med* 360:129–139, 2009
 7. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, for the RECORD Study Group: Rosiglitazone evaluated for cardiac outcomes—an interim analysis. *N Engl J Med* 357:28–38, 2007
 8. Nathan DM: Rosiglitazone and cardiotoxicity—weighing the evidence. *N Engl J Med* 357:64–66, 2007
 9. Eizirik DL: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes (Letter). *Diabetes Care* 32:e35, 2009. DOI: 10.2337/dc08-2275